Altamira Therapeutics (NASDAQ: CYTO) stock soared over 35% on Monday after the company partnered with Univercells Group to explore mRNA vaccine delivery.
Altamira Therapeutics (CYTO) has partnered with Univercells Group to evaluate the efficacy of its proprietary SemaPhore platform in mRNA vaccine delivery.
Under the terms of the agreement, Univercells will conduct experiments involving a proprietary mRNA vaccine delivered through Altamira’s SemaPhore nanoparticle platform. If these experiments yield favorable outcomes, both companies plan to discuss and negotiate a commercial agreement for developing and manufacturing nanoparticle-based mRNA vaccines utilizing Univercells’ production platform.
Covadonga Pañeda, Ph.D., Altamira’s Chief Operating Officer, expressed enthusiasm regarding the collaboration with Univercells, emphasizing the potential of SemaPhore as a delivery vehicle for mRNA vaccines.
She noted,
“SemaPhore has shown to be an efficient delivery vehicle for therapeutic RNA in many different disease models. With this collaboration, we will explore for the first time its potential utility in delivering mRNA vaccines.”
Altamira Therapeutics (NASDAQ: CYTO) Stock Performance
CYTO stock surged 35.84% to close at $2.35 on Monday. The traders had exchanged hands with 62,807,936(62.80 million) shares compared to the average daily trading volume of 1.20 M. The stock has a market capitalization of $3.71 million.
Edward Cooke is a financial analyst, freelance writer, and editor. He has six years of experience in financial journalism. He has an in-depth understanding of equities markets, tracking major indices and providing real-time analysis on stock price movements, corporate earnings, and market sentiment.
